Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo

Molecular Pharmacology

Volumn 79, Issue 1, 2011, Pages 157-166

  Blair, Brian G ^a,b   Larson, Christopher A ^a   Adams, Preston L ^a   Abada, Paolo B ^a   Pesce, Catherine E ^a,b   Safaei, Roohangiz ^a   Howell, Stephen B ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; CARRIER PROTEIN; CISPLATIN; COPPER TRANSPORTER 2; DEXTRAN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN CDC42; RAC1 PROTEIN; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOCYTOSIS; ENZYME ACTIVATION; EXOCYTOSIS; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SINGLE DRUG DOSE; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CATION TRANSPORT PROTEINS; CELL LINE; CISPLATIN; FEMALE; GENE KNOCKDOWN TECHNIQUES; MICE; MICE, KNOCKOUT; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PINOCYTOSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650972288     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.068411     Document Type: Article

References (54)

1. Andrews PA and Howell SB (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2:35-43.
2. Bellemare DR, Shaner L, Morano KA, Beaudoin J, Langlois R, and Labbe S (2002) Ctr6, a vacuolar membrane copper transporter in Schizosaccharomyces pombe. J Biol Chem 277:46676-46686.
3. Bertinato J, Swist E, Plouffe LJ, Brooks SP, and L'abbé MR (2008) Ctr2 is partially localized to the plasma membrane and stimulates copper uptake in COS-7 cells. Biochem J 409:731-740.
4. Blair BG, Larson CA, Adams PL, Abada PB, Safaei R, and Howell SB (2010) Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells. Mol Pharmacol 77:912-921.
5. Blair BG, Larson CA, Safaei R, and Howell SB (2009) Copper transporter 2 regulates the cellular accumulation and cytotoxicity of cisplatin and carboplatin. Clin Cancer Res 15:4312-4321.
6. Castanotto D and Rossi JJ (2009) The promises and pitfalls of RNA-interference-based therapeutics. Nature 457:426-433.
7. Chauhan SS, Liang XJ, Su AW, Pai-Panandiker A, Shen DW, Hanover JA, and Gottesman MM (2003) Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines. Br J Cancer 88:1327-1334.
8. Chu G (1994) Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 269:787-790.
9. Conner SD and Schmid SL (2003) Regulated portals of entry into the cell. Nature 422:37-44.
10. Crul M, Schellens JH, Beijnen JH, and Maliepaard M (1997) Cisplatin resistance and DNA repair. Cancer Treat Rev 23:341-366.
11. Dharmawardhane S, Schürmann A, Sells MA, Chernoff J, Schmid SL, and Bokoch GM (2000) Regulation of macropinocytosis by p21-activated kinase-1. Mol Biol Cell 11:3341-3352.
12. Finney L, Vogt S, Fukai T, and Glesne D (2009) Copper and angiogenesis: unravelling a relationship key to cancer progression. Clin Exp Pharmacol Physiol 36:88-94.
13. Gately DP and Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67:1171-1176.
14. Gupte A and Mumper RJ (2009) Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev 35:32-46.
15. Haremaki T, Fraser ST, Kuo YM, Baron MH, and Weinstein DC (2007) Vertebrate Ctr1 coordinates morphogenesis and progenitor cell fate and regulates embryonic stem cell differentiation. Proc Natl Acad Sci USA 104:12029-12034.
16. Holzer AK and Howell SB (2006) The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res 66:10944-10952.
17. Holzer AK, Manorek GH, and Howell SB (2006) Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol 70:1390-1394.
18. Iatropoulos MJ and Williams GM (1996) Proliferation markers. Exp Toxicol Pathol 48:175-181.
19. Ivanov AI (2008) Pharmacological inhibition of endocytic pathways: is it specific enough to be useful? Methods Mol Biol 440:15-33.
20. Jandial DD, Farshchi-Heydari S, Larson CA, Elliott GI, Wrasidlo WJ, and Howell SB (2009) Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clinical Cancer Research 15:553-560.
21. Johnson SW, Laub PB, Beesley JS, Ozols RF, and Hamilton TC (1997) Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 57:850-856.
22. Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo YM, Rochdi M, and Howell SB (2002) Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 62:6559-6565.
23. Kelland LR, Mistry P, Abel G, Freidlos F, Loh SY, Roberts JJ, and Harrap KR (1992) Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res 52:1710-1716.
24. Kuo MT, Chen HH, Song IS, Savaraj N, and Ishikawa T (2007) The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev 26:71-83.
25. Larson CA, Blair BG, Safaei R, and Howell SB (2009) The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol 75:324-330.
26. Latimer P, Menchaca M, Snyder RM, Yu W, Gilbert BE, Sanders BG, and Kline K (2009) Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases. Exp Biol Med (Maywood) 234:1244-1252.
27. Lee J, Petris MJ, and Thiele DJ (2002) Characterization of mouse embryonic cells deficient in the ctr1 high affinity copper transporter. Identification of a Ctr1-independent copper transport system. J Biol Chem 277:40253-40259.
28. Liang XJ, Mukherjee S, Shen DW, Maxfield FR, and Gottesman MM (2006) Endocytic recycling compartments altered in cisplatin-resistant cancer cells. Cancer Res 66:2346-2353.
29. Lucidarme O, Kono Y, Corbeil J, Choi SH, Golmard JL, Varner J, and Mattrey RF (2006) Angiogenesis: noninvasive quantitative assessment with contrast-enhanced functional US in murine model. Radiology 239:730-739.
30. Manic S, Gatti L, Carenini N, Fumagalli G, Zunino F, and Perego P (2003) Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 3:21-29.
31. Metcalfe SA, Cain K, and Hill BT (1986) Possible mechanism for differences in sensitivity to cis-platinum in human prostate tumor cell lines. Cancer Lett 31:163-169.
32. Muggia FM and Los G (1993) Platinum resistance: laboratory findings and clinical implications. Stem Cells 11:182-193.
33. Oldenburg J, Begg AC, van Vugt MJ, Ruevekamp M, Schornagel JH, Pinedo HM, and Los G (1994) Characterization of resistance mechanisms to cis-diamminedichloroplatinum(II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro. Cancer Res 54:487-493.
34. Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, De Carvalho M, Mesri EA, Robins DM, Dick RD, et al. (2002) Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 62:4854-4859.
35. Portnoy ME, Schmidt PJ, Rogers RS, and Culotta VC (2001) Metal transporters that contribute copper to metallochaperones in Saccharomyces cerevisiae. Mol Genet Genomics 265:873-882.
36. Rabik CA and Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9-23.
37. Rees EM, Lee J, and Thiele DJ (2004) Mobilization of intracellular copper stores by the ctr2 vacuolar copper transporter. J Biol Chem 279:54221-54229.
38. Safaei R and Howell SB (2005) Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 53:13-23.
39. Safaei R, Katano K, Samimi G, Holzer AK, Naerdemann W, and Howell SB (2004a) Contribution of endocytic pathways to the uptake of cisplatin in sensitive and resistant ovarian cancer cells. Proc Am Assoc Cancer Res 45:120.
40. Safaei R, Katano K, Samimi G, Naerdemann W, Stevenson JL, Rochdi M, and Howell SB (2004b) Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemother Pharmacol 53:239-246.
41. Safaei R, Maktabi MH, Blair BG, Larson CA, and Howell SB (2009) Effects of the loss of Atox1 on the cellular pharmacology of cisplatin. J Inorg Biochem 103:333-341.
42. Sedletska Y, Giraud-Panis MJ, and Malinge JM (2005) Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents 5:251-265.
43. Shen DW, Liang XJ, Gawinowicz MA, and Gottesman MM (2004a) Identification of cytoskeletal [14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines. Mol Pharmacol 66:789-793.
44. Shen DW, Su A, Liang XJ, Pai-Panandiker A, and Gottesman MM (2004b) Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br J Cancer 91:270-276.
45. Siomi MC (2009) Short interfering RNA-mediated gene silencing; towards successful application in human patients. Adv Drug Deliv Rev 61:668-671.
46. Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, and Kuo MT (2004) Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 3:1543-1549.
47. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, et al. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432:173-178.
48. Teicher BA, Holden SA, Herman TS, Sotomayor EA, Khandekar V, Rosbe KW, Brann TW, Korbut TT, and Frei E 3rd (1991) Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II). Int J Cancer 47:252-260.
49. Twentyman PR, Wright KA, Mistry P, Kelland LR, and Murrer BA (1992) Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res 52:5674-5680.
50. van den Berghe PV, Folmer DE, Malingré HE, van Beurden E, Klomp AE, van de Sluis B, Merkx M, Berger R, and Klomp LW (2007) Human copper transporter 2 is localized in late endosomes and lysosomes and facilitates cellular copper uptake. Biochem J 407:49-59.
51. Waud WR (1987) Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells. Cancer Res 47:6549-6555.
52. Yoshii J, Yoshiji H, Kuriyama S, Ikenaka Y, Noguchi R, Okuda H, Tsujinoue H, Nakatani T, Kishida H, Nakae D, et al. (2001) The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. Int J Cancer 94:768-773.
53. Yu Y, Wong J, Lovejoy DB, Kalinowski DS, and Richardson DR (2006) Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res 12:6876-6883.
54. Zorbas H and Keppler BK (2005) Cisplatin damage: are DNA repair proteins saviors or traitors to the cell? Chembiochem 6:1157-1166.